Bearish outlook at JPMorgan investor conference on TherapeuticsMD sinks shares, down 17%

• TherapeuticsMD (TXMD -16.6%) slumps on almost a 5x surge in volume apparently stoked by news of a short position by Lakewood Capital's Anthony Bozza, a featured speaker at JPMorgan's Robin Hood Investors Conference in New York.
• The company's U.S. marketing application for its estradiol softgel capsule (TX-004HR) for dyspareunia is currently under review. The FDA's action date is May 7, 2017.